News

  1. Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Pivotal Phase 3 Safety Trial For GTX-104 In aSAH Patients 7/10/2023

    Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104, today announced WuXi Clinical Development, Inc. ("WuXi Clinical"), a wholly owned subsidiary of WuXi AppTec, a global Contract Research Organization (CRO), will conduct Acasti's STRIVE-ON Phase 3 safety trial for GTX-104. GTX-104 is Acasti's novel, injectable nimodipine formulation for intravenous infusion (IV) that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH).

  2. Meissa Vaccines Enters Into cGMP Manufacturing Agreement For Pediatric RSV Vaccine Candidate For Phase 2 Clinical Trials 6/28/2023

    Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced it has entered into a manufacturing agreement with Exothera S.A. (“Exothera”), a Univercells company and full-service Contract Research Development and Manufacturing Organization (CRDMO) delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.

  3. Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation For Clopidogrel That Received IND Approval 6/27/2023

    Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia's patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA).

  4. Stevanato Group Presents Vertiva, A Versatile On-Body Delivery System Platform For A Wide Range Of Injectable Therapies And For Large Delivery Volumes (Up To 100mL) 6/12/2023

    Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies.

  5. Corning And SGD Pharma Announce Joint Venture To Open New Glass Tubing Facility And Expand Access To Corning Velocity Vial Technology In India 6/8/2023

    Corning Incorporated and SGD Pharma today announced a joint venture that includes the opening of a new glass tubing facility to expand pharmaceutical manufacturing in India and allows SGD Pharma to adopt Corning’s Velocity Vial technology platform.

  6. AustinPx Expands Development And Manufacturing Technologies 5/9/2023

    AustinPx, a contract development and manufacturing organization (CDMO) specializing in analytical and formulation development services and cGMP manufacturing for small molecule drugs, today announced the expansion of its capabilities to meet industry demand for the Company’s services and expertise.

  7. Viridian Therapeutics Announces Partnership With Drug Delivery Innovator Enable Injections 5/8/2023

    Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL.

  8. Moderna And Novocol Pharma Announce Fill-Finish Agreement For Canadian-Made mRNA Vaccines 5/4/2023

    Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a long-term agreement with Ontario-based Novocol Pharma, a leading sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada.

  9. SHL Medical And MoonLake Immunotherapeutics Collaborate To Develop Sonelokimab Autoinjector 5/3/2023

    SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, to develop an autoinjector for clinical and potential commercial supply of MoonLake's Nanobody® sonelokimab based on SHL Medical's Molly® autoinjector technology.

  10. Hovione And H&T Presspart Extend Partnership To Advance High Efficiency Device Technology For Dry Powder Inhalation Formulation Delivery 5/3/2023

    Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform.